Botensilimab and Balstilimab in Refractory Microsatellite Stable (MSS) mCRC
An overview of data presented at ESMO GI 2023 on combined botensilimab and balstilimab therapy in heavily pretreated patients with microsatellite stable metastatic colorectal cancer.
Source: ajmc.com